The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor

Современная онкология

V V Ryazhenov¹ 

[1] I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation;

关键词: non-small cell lung cancer;    mutations in the egfr gene;    targeted therapy;    small molecule tyrosine kinase inhibitors;    tyrosine kinase inhibitors;    afatinib;    gefitinib;    pharmacoeconomic analyses;    cost effectiveness;   

DOI  :  

来源: DOAJ

【 摘 要 】

This article deals with the pharmacoeconomic comparative analysis of different strategies of pharmacotherapy using low-molecular-weight tyrosine kinase inhibitors (afatinib and gefitinib) in patients with non-small cell lung cancer associated with mutation in the epidermal growth factor receptor (EGFR). We determined that gefitinib had clinical and economic benefits associated with the reducing financial costs and better cost effectiveness index.

【 授权许可】

Unknown